Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.

Abstract:

BACKGROUND:To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation. METHODS:A retrospective analysis was performed on 291 patients with GBM. The efficacies of VPA and LEV alone and as polytherapy were analyzed in 181 (62%) patients with seizures with a minimum follow-up of 6 months. Cox-regression survival analysis was performed on 165 patients receiving chemoradiation with temozolomide of whom 108 receiving this in combination with VPA for at least 3 months. RESULTS:Monotherapy with either VPA or LEV was instituted in 137/143 (95.8%) and in 59/86 (68.6%) on VPA/LEV polytherapy as the next regimen. Initial freedom from seizure was achieved in 41/100 (41%) on VPA, in 16/37 (43.3%) on LEV, and in 89/116 (76.7%) on subsequent VPA/LEV polytherapy. At the end of follow-up, seizure freedom was achieved in 77.8% (28/36) on VPA alone, in 25/36 (69.5%) on LEV alone, and in 38/63 (60.3%) on VPA/LEV polytherapy with ongoing seizures on monotherapy. Patients using VPA in combination with temozolomide showed a longer median survival of 69 weeks (95% confidence interval [CI]: 61.7-67.3) compared with 61 weeks (95% CI: 52.5-69.5) in the group without VPA (hazard ratio, 0.63; 95% CI: 0.43-0.92; P = .016), adjusting for age, extent of resection, and O(6)-DNA methylguanine-methyltransferase promoter methylation status. CONCLUSIONS:Polytherapy with VPA and LEV more strongly contributes to seizure control than does either as monotherapy. Use of VPA together with chemoradiation with temozolomide results in a 2-months' longer survival of patients with GBM.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Kerkhof M,Dielemans JC,van Breemen MS,Zwinkels H,Walchenbach R,Taphoorn MJ,Vecht CJ

doi

10.1093/neuonc/not057

subject

Has Abstract

pub_date

2013-07-01 00:00:00

pages

961-7

issue

7

eissn

1522-8517

issn

1523-5866

pii

not057

journal_volume

15

pub_type

杂志文章
  • Diffuse midline glioma with an H3 K27M mutation: A comparison integrating the clinical, radiological, molecular features between adult and pediatric patients.

    abstract:BACKGROUND:Diffuse midline glioma (DMG), H3 K27M-mutant occurs in both adult and pediatric populations. The characteristics of the two DMG groups were systematically explored in this study. METHODS: One-hundred-sixteen patients diagnosed with H3 K27M-mutant DMG in Beijing Tiantan Hospital from May 2016 to December 201...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,收录出版

    doi:10.1093/neuonc/noz152

    authors: Jiang H,Yang K,Ren X,Cui Y,Li M,Lei Y,Lin S

    更新日期:2019-08-24 00:00:00

  • Altered brain morphology after focal radiation reveals impact of off-target effects: implications for white matter development and neurogenesis.

    abstract:Background:Children with brain tumors treated with cranial radiation therapy (RT) often exhibit cognitive late effects, commonly associated with reduced white matter (WM) volume and decreased neurogenesis. The impact of radiation damage in particular regions or tissues on brain development as a whole has not been eluci...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox211

    authors: Beera KG,Li YQ,Dazai J,Stewart J,Egan S,Ahmed M,Wong CS,Jaffray DA,Nieman BJ

    更新日期:2018-05-18 00:00:00

  • Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.

    abstract::Grade II gliomas are morphologically and clinically heterogeneous tumors for which histopathological typing remains the major tool for clinical classification. To what extent the major histological subtypes - astrocytomas, oligodendrogliomas, and oligoastrocytomas - constitute true biological entities is largely unres...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-041

    authors: Hägerstrand D,Smits A,Eriksson A,Sigurdardottir S,Olofsson T,Hartman M,Nistér M,Kalimo H,Ostman A

    更新日期:2008-02-01 00:00:00

  • Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.

    abstract:Background:Glioblastoma cell-initiated vascularization is an alternative angiogenesis called vasculogenic mimicry. However, current knowledge on the mechanism of de novo vessel formation from glioblastoma stem cells (GSCs) is limited. Methods:Sixty-four glioblastoma samples from patients and 10 fluorescent glioma xeno...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox016

    authors: Mei X,Chen YS,Chen FR,Xi SY,Chen ZP

    更新日期:2017-08-01 00:00:00

  • Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

    abstract::Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression. We evaluated 56 patients with recurrent brain tumors wh...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/5.2.89

    authors: Meyers CA,Hess KR

    更新日期:2003-04-01 00:00:00

  • Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.

    abstract::The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intrav...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-043

    authors: Bradley KA,Pollack IF,Reid JM,Adamson PC,Ames MM,Vezina G,Blaney S,Ivy P,Zhou T,Krailo M,Reaman G,Mehta MP,Children's Oncology Group.

    更新日期:2008-10-01 00:00:00

  • Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.

    abstract:Background:Molecular profile of glioblastoma multiforme (GBM) revealed 4 subtypes, 2 of which, proneural and mesenchymal, have been predominantly observed, with the latter displaying a more aggressive phenotype and increased therapeutic resistance. Single-cell RNA sequencing revealed that multiple subtypes actually res...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/now253

    authors: Teng J,da Hora CC,Kantar RS,Nakano I,Wakimoto H,Batchelor TT,Chiocca EA,Badr CE,Tannous BA

    更新日期:2017-06-01 00:00:00

  • DNA repair after irradiation in glioma cells and normal human astrocytes.

    abstract::We examined DNA damage responses and repair in four human glioma cell lines (A7, U87, T98G, and U373) and normal human astrocytes (NHAs) after clinically relevant radiation doses to establish whether we could identify differences among them that might suggest new approaches to selective radiosensitization. We used pho...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-030

    authors: Short SC,Martindale C,Bourne S,Brand G,Woodcock M,Johnston P

    更新日期:2007-10-01 00:00:00

  • Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes.

    abstract::Treatment for medulloblastoma during childhood impairs neurocognitive function in survivors. While those diagnosed at younger ages are most vulnerable, little is known about the long-term neurocognitive, functional, and physical outcomes in survivors as they approach middle age. In this retrospective cohort study, we ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor015

    authors: Edelstein K,Spiegler BJ,Fung S,Panzarella T,Mabbott DJ,Jewitt N,D'Agostino NM,Mason WP,Bouffet E,Tabori U,Laperriere N,Hodgson DC

    更新日期:2011-05-01 00:00:00

  • Role of CX3CR1 signaling in malignant transformation of gliomas.

    abstract:BACKGROUND:Chemokine signaling may contribute to progression of low-grade gliomas (LGGs) by altering tumor behavior or impacting the tumor microenvironment. In this study, we investigated the role of CX3C chemokine receptor 1 (CX3CR1) signaling in malignant transformation of LGGs. METHODS:Ninety patients with LGGs wer...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa075

    authors: Lee S,Latha K,Manyam G,Yang Y,Rao A,Rao G

    更新日期:2020-10-14 00:00:00

  • Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway.

    abstract::Neuroblastomas, an embryonic cancer of the sympathetic nervous system, often occur in young children. Honokiol, a small-molecule polyphenol, has multiple therapeutic effects and pharmacological activities. This study was designed to evaluate whether honokiol could pass through the blood-brain barrier (BBB) and induce ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor217

    authors: Lin JW,Chen JT,Hong CY,Lin YL,Wang KT,Yao CJ,Lai GM,Chen RM

    更新日期:2012-03-01 00:00:00

  • Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

    abstract:BACKGROUND:Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic and epigenetic alterations are undefined but nonetheless highly relevant to combinatorial treatments. METHODS:Patients with CNS ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/now132

    authors: Garber ST,Hashimoto Y,Weathers SP,Xiu J,Gatalica Z,Verhaak RG,Zhou S,Fuller GN,Khasraw M,de Groot J,Reddy SK,Spetzler D,Heimberger AB

    更新日期:2016-10-01 00:00:00

  • A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.

    abstract:BACKGROUND:Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults, and its prognosis remains dismal despite intensive research and therapeutic advances. Diagnostic biomarkers would be clinically meaningful to allow for early detection of the tumor and for those cases in which surgery is cont...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not218

    authors: Manterola L,Guruceaga E,Gállego Pérez-Larraya J,González-Huarriz M,Jauregui P,Tejada S,Diez-Valle R,Segura V,Samprón N,Barrena C,Ruiz I,Agirre A,Ayuso A,Rodríguez J,González A,Xipell E,Matheu A,López de Munain A,Tuñón

    更新日期:2014-04-01 00:00:00

  • Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

    abstract::The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast mate...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox175

    authors: Sarkaria JN,Hu LS,Parney IF,Pafundi DH,Brinkmann DH,Laack NN,Giannini C,Burns TC,Kizilbash SH,Laramy JK,Swanson KR,Kaufmann TJ,Brown PD,Agar NYR,Galanis E,Buckner JC,Elmquist WF

    更新日期:2018-01-22 00:00:00

  • Adult pilocytic astrocytomas: clinical features and molecular analysis.

    abstract:BACKGROUND:Adult pilocytic astrocytomas (PAs) are rare and have an aggressive clinical course compared with pediatric patients. Constitutive Ras/RAF/MAPK signaling appears to be an important oncogenic event in sporadic PA. We evaluated clinical data and molecular profiles of adult PAs at our institution. METHODS:We id...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not246

    authors: Theeler BJ,Ellezam B,Sadighi ZS,Mehta V,Tran MD,Adesina AM,Bruner JM,Puduvalli VK

    更新日期:2014-06-01 00:00:00

  • Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

    abstract::Transforming growth factor-beta (TGF-beta) is a proinvasive and immunosuppressive cytokine that plays a major role in the malignant phenotype of gliomas. One novel strategy of disabling TGF-beta activity in gliomas is to disrupt the signaling cascade at the level of the TGF-beta receptor I (TGF-betaRI) kinase, thus ab...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-010

    authors: Tran TT,Uhl M,Ma JY,Janssen L,Sriram V,Aulwurm S,Kerr I,Lam A,Webb HK,Kapoun AM,Kizer DE,McEnroe G,Hart B,Axon J,Murphy A,Chakravarty S,Dugar S,Protter AA,Higgins LS,Wick W,Weller M,Wong DH

    更新日期:2007-07-01 00:00:00

  • A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

    abstract:BACKGROUND:Several lines of evidence suggest a T cell-mediated immune response in paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate whether suppression of T cell-mediated immune responses in Hu-PNS patients improved their neurological outcome, we performed a prospective ope...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou126

    authors: de Jongste AH,van Gelder T,Bromberg JE,de Graaf MT,Gratama JW,Schreurs MW,Hooijkaas H,Sillevis Smitt PA

    更新日期:2015-01-01 00:00:00

  • Limitations of stereotactic biopsy in the initial management of gliomas.

    abstract::Stereotactic biopsy is often performed for diagnostic purposes before treating patients whose imaging studies highly suggest glioma. Indications cited for biopsy include diagnosis and/or the "inoperability" of the tumor. This study questions the routine use of stereotactic biopsy in the initial management of gliomas. ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/3.3.193

    authors: Jackson RJ,Fuller GN,Abi-Said D,Lang FF,Gokaslan ZL,Shi WM,Wildrick DM,Sawaya R

    更新日期:2001-07-01 00:00:00

  • Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).

    abstract:BACKGROUND:Young age is a favorable prognostic factor for patients with glioblastoma multiforme (GBM). We reviewed the outcomes and molecular tumor characteristics of adolescent and young adult patients with GBM treated in 2 Austrian centers. PATIENTS AND METHODS:Data on patients with histologically proven primary GBM...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos283

    authors: Leibetseder A,Ackerl M,Flechl B,Wöhrer A,Widhalm G,Dieckmann K,Kreinecker SS,Pichler J,Hainfellner J,Preusser M,Marosi C

    更新日期:2013-01-01 00:00:00

  • Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors.

    abstract:BACKGROUND:Controversy exists as to what may be defined as standard of care (including markers for stratification) for patients with atypical teratoid/rhabdoid tumors (ATRTs). The European Rhabdoid Registry (EU-RHAB) recruits uniformly treated patients and offers standardized genetic and DNA methylation analyses. METH...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz244

    authors: Frühwald MC,Hasselblatt M,Nemes K,Bens S,Steinbügl M,Johann PD,Kerl K,Hauser P,Quiroga E,Solano-Paez P,Biassoni V,Gil-da-Costa MJ,Perek-Polnik M,van de Wetering M,Sumerauer D,Pears J,Stabell N,Holm S,Hengartner H,Ge

    更新日期:2020-07-07 00:00:00

  • Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

    abstract::Antiangiogenic therapy is associated with increased radiographic responses in glioblastomas, but tumors invariably recur. Because tumor-associated macrophages have been shown to mediate escape from antiangiogenic therapy in preclinical models, we examined the role of macrophages in patients with recurrent glioblastoma...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not082

    authors: Lu-Emerson C,Snuderl M,Kirkpatrick ND,Goveia J,Davidson C,Huang Y,Riedemann L,Taylor J,Ivy P,Duda DG,Ancukiewicz M,Plotkin SR,Chi AS,Gerstner ER,Eichler AF,Dietrich J,Stemmer-Rachamimov AO,Batchelor TT,Jain RK

    更新日期:2013-08-01 00:00:00

  • Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT.

    abstract::Medulloblastomas are the most common malignant tumors of the central nervous system during childhood. Radiation-induced medulloblastoma tumor recurrences are aggressive and metastatic in nature. In the present study, we demonstrate that Gadd45a expression can sensitize medulloblastoma cells to radiotherapy. We have el...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor109

    authors: Asuthkar S,Nalla AK,Gondi CS,Dinh DH,Gujrati M,Mohanam S,Rao JS

    更新日期:2011-10-01 00:00:00

  • The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

    abstract:Background:There have been few treatment advances for patients with glioblastoma (GBM) despite increasing scientific understanding of the disease. While factors such as intrinsic tumor biology and drug delivery are challenges to developing efficacious therapies, it is unclear whether the current clinical trial landscap...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,meta分析

    doi:10.1093/neuonc/noy027

    authors: Vanderbeek AM,Rahman R,Fell G,Ventz S,Chen T,Redd R,Parmigiani G,Cloughesy TF,Wen PY,Trippa L,Alexander BM

    更新日期:2018-07-05 00:00:00

  • Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

    abstract:BACKGROUND:Mutations involving isocitrate dehydrogenase 1 (IDH 1) occur in a high proportion of diffuse gliomas, with implications on diagnosis and prognosis. About 90% involve exon 4 at codon 132, replacing amino acid arginine with histidine (R132H). Rarer ones include R132C, R132S, R132G, R132L, R132V, and R132P. Mos...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not015

    authors: Agarwal S,Sharma MC,Jha P,Pathak P,Suri V,Sarkar C,Chosdol K,Suri A,Kale SS,Mahapatra AK,Jha P

    更新日期:2013-06-01 00:00:00

  • Assessment and treatment relevance in elderly glioblastoma patients.

    abstract::Glioblastoma (GBM) is the most common malignant primary brain tumor. Its incidence continues to increase in the elderly because the older segment of the population is growing faster than any other age group. Most clinical studies exclude elderly patients, and "standards of care" do not exist for GBM patients aged >70 ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou063

    authors: Bauchet L,Zouaoui S,Darlix A,Menjot de Champfleur N,Ferreira E,Fabbro M,Kerr C,Taillandier L

    更新日期:2014-11-01 00:00:00

  • Enhanced expression of coproporphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA-induced fluorescence.

    abstract::In photodynamic diagnosis, 5-aminolevulinic acid (5-ALA) is widely used for the fluorescence-guided resection of malignant brain tumors, where 5-ALA is converted to protoporphyrin IX, which exhibits strong fluorescence. Little is known, however, about the detailed molecular mechanisms underlying 5-ALA-induced fluoresc...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,收录出版

    doi:10.1093/neuonc/nor116

    authors: Takahashi K,Ikeda N,Nonoguchi N,Kajimoto Y,Miyatake S,Hagiya Y,Ogura S,Nakagawa H,Ishikawa T,Kuroiwa T

    更新日期:2011-11-01 00:00:00

  • AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

    abstract::Neurofibromatosis type 2 (NF2) is an autosomal-dominant disease that results in the formation of bilateral vestibular schwannomas (VSs) and multiple meningiomas. Treatment options for NF2-associated tumors are limited, and to date, no medical therapies are FDA approved. The ideal chemotherapeutic agent would inhibit b...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor072

    authors: Bush ML,Oblinger J,Brendel V,Santarelli G,Huang J,Akhmametyeva EM,Burns SS,Wheeler J,Davis J,Yates CW,Chaudhury AR,Kulp S,Chen CS,Chang LS,Welling DB,Jacob A

    更新日期:2011-09-01 00:00:00

  • Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.

    abstract:BACKGROUND:Meningiomas are the most commonly diagnosed primary intracranial neoplasms. Despite significant advances in modern therapies, the management of malignant meningioma and skull base meningioma remains a challenge. Thus, the development of new treatment modalities is urgently needed for these difficult-to-treat...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not007

    authors: Iwami K,Natsume A,Ohno M,Ikeda H,Mineno J,Nukaya I,Okamoto S,Fujiwara H,Yasukawa M,Shiku H,Wakabayashi T

    更新日期:2013-06-01 00:00:00

  • SPARC affects glioma cell growth differently when grown on brain ECM proteins in vitro under standard versus reduced-serum stress conditions.

    abstract::Secreted protein acidic and rich in cysteine (SPARC) has a suppressive effect on U87 glioma cell proliferation when assessed in vitro and in vivo using parental U87T2 and U87T2-derived SPARC-transfected clones. Since SPARCinteracts with extracellular matrix (ECM) proteins, we examined the effect of SPARC secretion on ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/5.4.244

    authors: Vadlamuri SV,Media J,Sankey SS,Nakeff A,Divine G,Rempel SA

    更新日期:2003-10-01 00:00:00

  • Understanding brain penetrance of anticancer drugs.

    abstract::This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy018

    authors: Levin VA,Ellingson BM

    更新日期:2018-04-09 00:00:00